↓ Skip to main content

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Overview of attention for article published in Biology of Blood & Marrow Transplantation, August 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
8 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
Published in
Biology of Blood & Marrow Transplantation, August 2018
DOI 10.1016/j.bbmt.2018.02.020
Pubmed ID
Authors

Yago Nieto, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Sairah Ahmed, Paolo Anderlini, Uday Popat, Roy B. Jones, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Partow Kebriaei, Amin Alousi, Melissa Timmons, Alison Gulbis, Alan Myers, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Sarah Milgrom, Richard Champlin, Borje S. Andersson

Abstract

We conducted a prospective phase 2 trial of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) with autologous stem-cell transplantation (ASCT) in Hodgkin's lymphoma (HL) patients with primary refractory or poor-risk relapsed disease (extranodal relapse or within 1 year of frontline therapy). The trial was powered to detect a 2-year progression-free survival (PFS) rate improvement from a historical 50% (using BEAM) to 65%. We compared the study population with all other concurrent patients who were eligible for the trial but instead received BEAM at our center. No patient received post-ASCT maintenance. The Gem/Bu/Mel trial enrolled 80 patients: median age 31, 41% primary refractory and 59% relapsed (36% extranodal relapses), and 30% PET-positive lesions at ASCT. The concurrent BEAM (N=45) and Gem/Bu/Mel cohorts were well balanced except for more Gem/Bu/Mel patients with bulky relapses and PET-positive tumors. There were no transplant-related deaths in either cohort. At median follow-up of 34.5 months (range, 26-72), Gem/Bu/Mel resulted in improved 2-year PFS (65% vs. 51%) (P=0.008) and overall survival (89% vs. 73%, P=0.0003). In conclusion, Gem/Bu/Mel is safe, yielding, in this nonrandomized comparison, improved outcomes compared with a concurrently treated and prognostically matched cohort of primary refractory or poor-risk relapsed HL patients receiving BEAM.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 27%
Unspecified 2 18%
Other 2 18%
Student > Postgraduate 1 9%
Student > Doctoral Student 1 9%
Other 2 18%
Readers by discipline Count As %
Medicine and Dentistry 4 36%
Unspecified 3 27%
Agricultural and Biological Sciences 2 18%
Social Sciences 1 9%
Biochemistry, Genetics and Molecular Biology 1 9%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2018.
All research outputs
#3,591,525
of 13,789,144 outputs
Outputs from Biology of Blood & Marrow Transplantation
#695
of 2,502 outputs
Outputs of similar age
#90,202
of 272,709 outputs
Outputs of similar age from Biology of Blood & Marrow Transplantation
#33
of 139 outputs
Altmetric has tracked 13,789,144 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,502 research outputs from this source. They receive a mean Attention Score of 4.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,709 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.